{"filing":{"accession_number":"0001549595-26-000030","cik":"0001549595","ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"nrix-20260606.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm"},"events":[{"id":6328,"run_id":5544,"accession_number":"0001549595-26-000030","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Nurix entered into a material License and Collaboration Agreement with Roche involving an exclusive worldwide license to develop and commercialize bexobrutideg. The transaction includes a $700 million upfront payment and up to $2.3 billion in total potential payments, with Nurix retaining co-development and co-commercialization rights in the U.S. and receiving royalties on ex-U.S. sales.","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5023,"accession_number":"0001549595-26-000030","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Nurix entered into a material License and Collaboration Agreement with Roche involving an exclusive worldwide license to develop and commercialize bexobrutideg. The transaction includes a $700 million upfront payment and up to $2.3 billion in total potential payments, with Nurix retaining co-development and co-commercialization rights in the U.S. and receiving royalties on ex-U.S. sales. This constitutes a material strategic transaction that would significantly affect investor assessment of the company's financial position and product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:13:08.409797+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5024,"accession_number":"0001549595-26-000030","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Nurix's \"entry into the Collaboration Agreement\" with Roche, a major pharmaceutical company. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01, the substance is a material collaboration or partnership agreement that would affect investor assessment of the company's strategic direction and revenue prospects. The company is hosting a conference call to discuss this collaboration, underscoring its materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:13:08.409797+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5023,"accession_number":"0001549595-26-000030","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Nurix entered into a material License and Collaboration Agreement with Roche involving an exclusive worldwide license to develop and commercialize bexobrutideg. The transaction includes a $700 million upfront payment and up to $2.3 billion in total potential payments, with Nurix retaining co-development and co-commercialization rights in the U.S. and receiving royalties on ex-U.S. sales. This constitutes a material strategic transaction that would significantly affect investor assessment of the company's financial position and product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:13:08.409797+00:00","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-08"},{"id":5024,"accession_number":"0001549595-26-000030","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Nurix's \"entry into the Collaboration Agreement\" with Roche, a major pharmaceutical company. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01, the substance is a material collaboration or partnership agreement that would affect investor assessment of the company's strategic direction and revenue prospects. The company is hosting a conference call to discuss this collaboration, underscoring its materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:13:08.409797+00:00","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-06-08"}]}